Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Everolimus
Related studies linked through entity extraction aliases.
Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
- Status
- COMPLETED
- Phase
- PHASE2
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A
- Status
- COMPLETED
- Phase
- PHASE4
Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
- Status
- TERMINATED
- Phase
- PHASE2
Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
- Status
- UNKNOWN
- Phase
- PHASE2
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Phase II Study of Everolimus Beyond Progression
- Status
- TERMINATED
- Phase
- PHASE2
OPALINE : A Study Of Morbidity And Mortality At 2 Years
- Status
- COMPLETED
- Phase
- N/A
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
- Status
- COMPLETED
- Phase
- PHASE4
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score
- Status
- TERMINATED
- Phase
- PHASE2
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
- Status
- UNKNOWN
- Phase
- PHASE2
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2